HUE068985T2 - FIMH mutáns, ezt tartalmazó készítmények és ezek alkalmazása - Google Patents

FIMH mutáns, ezt tartalmazó készítmények és ezek alkalmazása

Info

Publication number: HUE068985T2
Authority: HU; Hungary
Prior art keywords: compositions therewith; fimh; mutant; fimh mutant; therewith
Prior art date: 2020-01-16

Application number

HUE21700027A

Other languages

English (en)

Inventor

Jan Grijpstra

Eveline Weerdenburg

Jeroen Geurtsen

Kellen Fae

Louris Feitsma

Original Assignee

Janssen Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2020-01-16

Filing date

2021-01-14

Publication date

2025-02-28

2021-01-14 Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc

2025-02-28 Publication of HUE068985T2 publication Critical patent/HUE068985T2/hu

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0266—Klebsiella
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)

HUE21700027A 2020-01-16 2021-01-14 FIMH mutáns, ezt tartalmazó készítmények és ezek alkalmazása HUE068985T2 (hu)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP20152217		2020-01-16

Publications (1)

Publication Number	Publication Date
HUE068985T2 true HUE068985T2 (hu)	2025-02-28

Family

ID=69174406

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HUE21700027A HUE068985T2 (hu)	2020-01-16	2021-01-14	FIMH mutáns, ezt tartalmazó készítmények és ezek alkalmazása

Country Status (23)

Country	Link
US (3)	US11421003B2 (hu)
EP (2)	EP4090363B1 (hu)
JP (2)	JP7485771B2 (hu)
KR (1)	KR20220128372A (hu)
CN (1)	CN115038461A (hu)
AR (1)	AR121066A1 (hu)
AU (1)	AU2021208493B2 (hu)
BR (1)	BR112022013720A2 (hu)
CA (1)	CA3168108A1 (hu)
DK (1)	DK4090363T3 (hu)
ES (1)	ES2987890T3 (hu)
FI (1)	FI4090363T3 (hu)
HR (1)	HRP20241370T1 (hu)
HU (1)	HUE068985T2 (hu)
IL (1)	IL294445B2 (hu)
LT (1)	LT4090363T (hu)
MX (1)	MX2022008830A (hu)
PL (1)	PL4090363T3 (hu)
PT (1)	PT4090363T (hu)
RS (1)	RS66031B1 (hu)
SA (1)	SA522433319B1 (hu)
SI (1)	SI4090363T1 (hu)
WO (1)	WO2021144369A1 (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11260119B2 (en)	2018-08-24	2022-03-01	Pfizer Inc.	Escherichia coli compositions and methods thereof
HUE068985T2 (hu)	2020-01-16	2025-02-28	Janssen Pharmaceuticals Inc	FIMH mutáns, ezt tartalmazó készítmények és ezek alkalmazása
US12138302B2 (en)	2020-10-27	2024-11-12	Pfizer Inc.	Escherichia coli compositions and methods thereof
US20220202923A1 (en) *	2020-12-23	2022-06-30	Pfizer Inc.	E. coli fimh mutants and uses thereof
CA3207841A1 (en)	2021-01-12	2022-07-21	Janssen Pharmaceuticals, Inc	Fimh mutants, compositions therewith and use thereof
CA3242476A1 (en) *	2021-12-17	2023-06-22	Pfizer Inc.	Polynucleotide compositions and uses thereof
WO2023227608A1 (en)	2022-05-25	2023-11-30	Glaxosmithkline Biologicals Sa	Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4866034A (en)	1982-05-26	1989-09-12	Ribi Immunochem Research Inc.	Refined detoxified endotoxin
US4436727A (en)	1982-05-26	1984-03-13	Ribi Immunochem Research, Inc.	Refined detoxified endotoxin product
US4987237A (en)	1983-08-26	1991-01-22	Ribi Immunochem Research, Inc.	Derivatives of monophosphoryl lipid A
US4877611A (en)	1986-04-15	1989-10-31	Ribi Immunochem Research Inc.	Vaccine containing tumor antigens and adjuvants
US5057540A (en)	1987-05-29	1991-10-15	Cambridge Biotech Corporation	Saponin adjuvant
US4912094B1 (en)	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
WO1990014837A1 (en)	1989-05-25	1990-12-13	Chiron Corporation	Adjuvant formulation comprising a submicron oil droplet emulsion
JPH0655749B2 (ja)	1989-09-20	1994-07-27	日本たばこ産業株式会社	リピッドａ単糖類縁体
US5370872A (en)	1991-08-12	1994-12-06	Swiss Serum And Vaccine Institute Berne	Escherichia coliO-polysaccharide-protein conjugate vaccine
US5593969A (en)	1991-09-03	1997-01-14	Igen Incorporated	Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors
DK0761231T3 (da)	1992-06-25	2000-05-08	Smithkline Beecham Biolog	Vaccinepræparat indeholdende adjuvanser
UA56132C2 (uk)	1995-04-25	2003-05-15	Смітклайн Бічем Байолоджікалс С.А.	Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
ES2227825T3 (es)	1997-04-01	2005-04-01	Corixa Corporation	Composiciones inmunologicas aduvantes acuosas de monofosforil lipido a.
US6491919B2 (en)	1997-04-01	2002-12-10	Corixa Corporation	Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US6500434B1 (en)	1998-04-23	2002-12-31	Medimmune, Inc.	Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections
US6858211B1 (en)	1998-07-20	2005-02-22	The United States Of America As Represented By The Department Of Health And Human Services	Vaccines against Escherichia coli O157 infection
DK1126876T3 (da)	1998-10-16	2007-07-02	Glaxosmithkline Biolog Sa	Adjuvanssystemer og vacciner
AU1431101A (en)	1999-10-04	2001-05-10	University Of Maryland Biotechnology Institute	Novel adjuvant comprising a lipopolysaccharide antagonist
EP1385541B1 (en)	2000-04-13	2008-06-18	Corixa Corporation	Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
AU2001271907A1 (en)	2000-07-07	2002-01-21	Medimmune, Inc.	FimH adhesin proteins and methods of use
CA2420234A1 (en)	2000-08-18	2002-02-28	Medimmune, Inc.	Method of administering fimh protein as a vaccine for urinary tract infections
AU2001297896A1 (en) *	2000-12-08	2003-01-02	Medimmune, Inc.	Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
US6676958B2 (en)	2001-06-19	2004-01-13	Advanced Bioadjuvants, Llc	Adjuvant composition for mucosal and injection delivered vaccines
JP5185813B2 (ja)	2005-04-26	2013-04-17	エーザイ・アール・アンド・ディー・マネジメント株式会社	癌免疫治療のための組成物および方法
DK1888761T3 (da)	2005-05-11	2010-11-01	Eth Zuerich	Rekombinante N-glycosylerede proteiner fra prokaryote celler
TWI457133B (zh)	2005-12-13	2014-10-21	Glaxosmithkline Biolog Sa	新穎組合物
ES2376492T3 (es)	2006-03-23	2012-03-14	Novartis Ag	Compuestos de imidazoquinoxalina como inmunomoduladores.
ES2388556T3 (es)	2006-03-23	2012-10-16	Novartis Ag	Compuestos inmunopotenciadores
SI2257307T1 (sl)	2008-02-20	2018-09-28	Glaxosmithkline Biologicals S.A.	Biokonjugati, izdelani iz rekombinantnih N-glikoziliranih proteinov iz prokariontskih celic
AU2010256461B2 (en)	2009-06-05	2016-03-17	Access To Advanced Health Institute	Synthetic glucopyranosyl lipid adjuvants
HUE044841T2 (hu)	2012-02-07	2019-11-28	Infectious Disease Res Inst	TLR4 agonistákat tartalmazó javított adjuváns készítmények és azok alkalmazási eljárásai
MX354057B (es)	2013-05-18	2018-02-09	The Regents Of The Univ Of California Star	Composiciones y métodos para activar la señalización dependiente del "estimulador del gene de interferón".
US9149521B2 (en)	2013-09-25	2015-10-06	Sequoia Sciences, Inc.	Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en)	2013-09-25	2016-11-29	Sequoia Sciences, Inc	Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9415097B2 (en)	2013-09-25	2016-08-16	Sequoia Sciences, Inc.	Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9017698B2 (en)	2013-09-25	2015-04-28	Sequoia Sciences, Inc.	Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) *	2013-09-25	2015-10-06	Sequoia Sciences, Inc.	Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9415101B2 (en)	2013-09-25	2016-08-16	Sequoia Sciences, Inc.	Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
DK3110441T5 (da)	2014-02-24	2024-10-14	Glaxosmithkline Biologicals Sa	Hidtil ukendt polysaccharid og anvendelser deraf
EP3294761A4 (en)	2015-05-13	2019-04-03	University of Washington	COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF UROPATHOGEN E. COLI
EP3319633B1 (en)	2015-07-07	2020-11-11	Janssen Vaccines & Prevention B.V.	Vaccine against rsv
TWI715617B (zh)	2015-08-24	2021-01-11	比利時商葛蘭素史密斯克藍生物品公司	對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
TW202003023A (zh)	2018-03-12	2020-01-16	美商詹森藥物公司	針對尿路感染之疫苗
CA3165429A1 (en)	2019-12-20	2021-06-24	Vib Vzw	Nanobody exchange chromatography
HUE068985T2 (hu)	2020-01-16	2025-02-28	Janssen Pharmaceuticals Inc	FIMH mutáns, ezt tartalmazó készítmények és ezek alkalmazása
CA3207841A1 (en)	2021-01-12	2022-07-21	Janssen Pharmaceuticals, Inc	Fimh mutants, compositions therewith and use thereof

2021
- 2021-01-14 HU HUE21700027A patent/HUE068985T2/hu unknown
- 2021-01-14 WO PCT/EP2021/050707 patent/WO2021144369A1/en active Application Filing
- 2021-01-14 SI SI202130194T patent/SI4090363T1/sl unknown
- 2021-01-14 JP JP2022542383A patent/JP7485771B2/ja active Active
- 2021-01-14 KR KR1020227026828A patent/KR20220128372A/ko active Pending
- 2021-01-14 PL PL21700027.2T patent/PL4090363T3/pl unknown
- 2021-01-14 PT PT217000272T patent/PT4090363T/pt unknown
- 2021-01-14 AU AU2021208493A patent/AU2021208493B2/en active Active
- 2021-01-14 CA CA3168108A patent/CA3168108A1/en active Pending
- 2021-01-14 MX MX2022008830A patent/MX2022008830A/es unknown
- 2021-01-14 FI FIEP21700027.2T patent/FI4090363T3/fi active
- 2021-01-14 BR BR112022013720A patent/BR112022013720A2/pt unknown
- 2021-01-14 LT LTEPPCT/EP2021/050707T patent/LT4090363T/lt unknown
- 2021-01-14 ES ES21700027T patent/ES2987890T3/es active Active
- 2021-01-14 DK DK21700027.2T patent/DK4090363T3/da active
- 2021-01-14 EP EP21700027.2A patent/EP4090363B1/en active Active
- 2021-01-14 HR HRP20241370TT patent/HRP20241370T1/hr unknown
- 2021-01-14 IL IL294445A patent/IL294445B2/en unknown
- 2021-01-14 RS RS20241096A patent/RS66031B1/sr unknown
- 2021-01-14 EP EP24189800.6A patent/EP4461744A3/en active Pending
- 2021-01-14 CN CN202180009530.0A patent/CN115038461A/zh active Pending
- 2021-01-15 US US17/150,025 patent/US11421003B2/en active Active
- 2021-01-15 AR ARP210100099A patent/AR121066A1/es unknown
2022
- 2022-07-16 SA SA522433319A patent/SA522433319B1/ar unknown
- 2022-07-26 US US17/814,966 patent/US12012435B2/en active Active
2023
- 2023-12-26 JP JP2023218988A patent/JP2024045126A/ja active Pending
2024
- 2024-05-06 US US18/655,708 patent/US20240294582A1/en active Pending

Also Published As

Publication number	Publication date
WO2021144369A1 (en)	2021-07-22
TW202140521A (zh)	2021-11-01
PT4090363T (pt)	2024-09-19
JP7485771B2 (ja)	2024-05-16
MX2022008830A (es)	2022-10-07
LT4090363T (lt)	2024-09-25
ES2987890T3 (es)	2024-11-18
IL294445B2 (en)	2023-10-01
CN115038461A (zh)	2022-09-09
SI4090363T1 (sl)	2024-10-30
DK4090363T3 (da)	2024-09-30
AR121066A1 (es)	2022-04-13
EP4461744A3 (en)	2025-01-08
RS66031B1 (sr)	2024-11-29
JP2024045126A (ja)	2024-04-02
EP4090363A1 (en)	2022-11-23
US11421003B2 (en)	2022-08-23
US12012435B2 (en)	2024-06-18
PL4090363T3 (pl)	2024-11-25
IL294445B1 (en)	2023-06-01
IL294445A (en)	2022-09-01
CA3168108A1 (en)	2021-07-22
US20230049056A1 (en)	2023-02-16
KR20220128372A (ko)	2022-09-20
AU2021208493A1 (en)	2022-06-30
AU2021208493B2 (en)	2023-03-30
EP4461744A2 (en)	2024-11-13
EP4090363B1 (en)	2024-09-04
SA522433319B1 (ar)	2024-07-10
BR112022013720A2 (pt)	2022-10-11
JP2023500749A (ja)	2023-01-10
HRP20241370T1 (hr)	2024-12-20
FI4090363T3 (fi)	2024-09-25
US20240294582A1 (en)	2024-09-05
US20210221856A1 (en)	2021-07-22

Publication	Publication Date	Title
LT4090363T (lt)	2024-09-25	Fimh mutantas, kompozicijos su juo ir jų panaudojimas
GB202006481D0 (en)	2020-06-17	Composition and use thereof
GB202304235D0 (en)	2023-05-10	Compositions, methods and uses
PL4103161T3 (pl)	2024-05-27	Kompozycje i ich zastosowania
IL269723A (en)	2019-11-28	Mixtures containing mutant alpha-1-antitrypsin and their use
GB202107254D0 (en)	2021-07-07	Compositions and use thereof
PL4168523T3 (pl)	2024-11-04	Kompozycje i ich zastosowanie
GB202114798D0 (en)	2021-12-01	New uses and compositions
GB202016094D0 (en)	2020-11-25	New compositions and uses thereof
GB202014427D0 (en)	2020-10-28	Composition and use
GB202111289D0 (en)	2021-09-15	Compositions and uses thereof
GB202110657D0 (en)	2021-09-08	Compositions and uses thereof
GB202107615D0 (en)	2021-07-14	Compositions and uses thereof
GB202107614D0 (en)	2021-07-14	Compositions and uses thereof
GB202105108D0 (en)	2021-05-26	Compositions and uses thereof
GB202018414D0 (en)	2021-01-06	Compositions and uses thereof
GB202016490D0 (en)	2020-12-02	Compositions and uses thereof
GB202016492D0 (en)	2020-12-02	Compositions and uses thereof
GB202012123D0 (en)	2020-09-16	Compositions and uses thereof
GB202011443D0 (en)	2020-09-09	Compositions and uses thereof
GB202009268D0 (en)	2020-07-29	Compositions and uses thereof
GB202007851D0 (en)	2020-07-08	Compositions and uses thereof
GB202007850D0 (en)	2020-07-08	Compositions and uses thereof
GB202007753D0 (en)	2020-07-08	Compositions and uses thereof
GB202006436D0 (en)	2020-06-17	Compositions and uses thereof